Effect of growth hormone, epidermal growth factor, and insulin on bacterial translocation in experimental short bowel syndrome

2000 ◽  
Vol 35 (5) ◽  
pp. 692-695 ◽  
Author(s):  
I. Eizaguirre ◽  
P. Aldazabal ◽  
M.J. Barrena ◽  
J.M. Garcia-Arenzana ◽  
C. Ariz ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Short Bowel Syndrome ◽  
Bacterial Translocation ◽  
Short Bowel ◽  
Epidermal Growth

scholarly journals Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome

2017 ◽  
Vol 312 (4) ◽  
pp. G390-G404 ◽  
Author(s):  
David W. Lim ◽  
Crystal L. Levesque ◽  
Donna F. Vine ◽  
Mitsuru Muto ◽  
Jacob R. Koepke ◽  
...  
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Short Bowel Syndrome ◽  
Intestinal Adaptation ◽  
Villus Height ◽  
Short Bowel ◽  
Intestinal Length ◽  
Epidermal Growth ◽  
Glucagon Like Peptide

Glucagon-like peptide-2 (GLP-2) and epidermal growth factor (EGF) treatment enhance intestinal adaptation. To determine whether these growth factors exert synergistic effects on intestinal growth and function, GLP-2 and EGF-containing media (EGF-cm) were administered, alone and in combination, in neonatal piglet models of short bowel syndrome (SBS). Neonatal Landrace-Large White piglets were block randomized to 75% midintestinal [jejunoileal (JI) group] or distal intestinal [jejunocolic (JC) group] resection or sham control, with 7-day infusion of saline (control), intravenous human GLP-2 (11 nmol·kg−1·day−1) alone, enteral EGF-cm (80 μg·kg−1·day−1) alone, or GLP-2 and EGF-cm in combination. Adaptation was assessed by intestinal length, histopathology, Üssing chamber analysis, and real-time quantitative PCR of intestinal growth factors. Combined EGF-cm and GLP-2 treatment increased intestinal length in all three surgical models ( P < 0.01). EGF-cm alone selectively increased bowel weight per length and jejunal villus height in the JI group only. The JC group demonstrated increased intestinal weight and villus height ( P < 0.01) when given either GLP-2 alone or in combination with EGF-cm, with no effect of EGF-cm alone. Jejunal permeability of mannitol and polyethylene glycol decreased with combination therapy in both SBS groups ( P < 0.05). No difference was observed in fat absorption or body weight gain. IGF-1 mRNA was differentially expressed in JI vs. JC piglets with treatment. Combined treatment with GLP-2 and EGF-cm induced intestinal lengthening and decreased permeability, in addition to the trophic effects of GLP-2 alone. Our findings demonstrate the benefits of novel combination GLP-2 and EGF treatment for neonatal SBS, especially in the JC model representing most human infants with SBS. NEW & NOTEWORTHY Glucagon-like peptide-2 (GLP-2) and epidermal growth factor (EGF) are intestinotrophic, with demonstrated benefit in both animal models and human studies of short bowel syndrome (SBS). The current research shows that over and above known trophic effects, the combination of GLP-2 and EGF synergistically lengthens the bowel in neonatal piglet models of SBS. Most notable benefit occurred with resection of the terminal ileum, the common clinical anatomy seen in neonatal SBS and associated with least de novo lengthening postsurgery.

A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome

2005 ◽  
Vol 40 (5) ◽  
pp. 763-768 ◽  
Author(s):  
David L. Sigalet ◽  
Gary R. Martin ◽  
J. Decker Butzner ◽  
Andre Buret ◽  
Jonathan B. Meddings
Keyword(s):  
Pilot Study ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Short Bowel Syndrome ◽  
Short Bowel ◽  
Epidermal Growth

A pilot study of the use of epidermal growth factor in treating pediatric short bowel syndrome

2003 ◽  
Vol 124 (4) ◽  
pp. A430
Author(s):  
David Sigalet ◽  
Gary Martin ◽  
Jon Meddings ◽  
Andre Buret ◽  
James Hardin ◽  
...  
Keyword(s):  
Pilot Study ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Short Bowel Syndrome ◽  
Short Bowel ◽  
Epidermal Growth

Interaction of Growth Hormone-Releasing Factor and Somatostatin on Ulcer Healing and Mucosal Growth in Rats: Role of Gastrin and Epidermal Growth Factor

Digestion ◽  
1988 ◽  
Vol 41 (3) ◽  
pp. 121-128 ◽  
Author(s):  
S.J. Konturek ◽  
T. Brzozowski ◽  
A. Dembinski ◽  
Z. Warzecha ◽  
P.K. Konturek ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Ulcer Healing ◽  
Growth Hormone Releasing Factor ◽  
Epidermal Growth ◽  
Mucosal Growth

scholarly journals Prolactin, Growth Hormone, and Epidermal Growth Factor Activate Stat5 in Different Compartments of Mammary Tissue and Exert Different and Overlapping Developmental Effects

2001 ◽  
Vol 229 (1) ◽  
pp. 163-175 ◽  
Author(s):  
Marta I. Gallego ◽  
Nadine Binart ◽  
Gertraud W. Robinson ◽  
Ryugo Okagaki ◽  
Karen T. Coschigano ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Mammary Tissue ◽  
Developmental Effects ◽  
Epidermal Growth

Changes in protein metabolism of ovine primary muscle cultures on treatment with growth hormone, insulin, insulin-like growth factor I or epidermal growth factor

1987 ◽  
Vol 112 (1) ◽  
pp. 87-96 ◽  
Author(s):  
J. M. M. Harper ◽  
J. B. Soar ◽  
P. J. Buttery
Keyword(s):  
Growth Hormone ◽  
Protein Synthesis ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Muscle Cultures ◽  
Epidermal Growth ◽  
Growth Factor I ◽  
High Concentrations

ABSTRACT Methods for the primary culture of muscle cells from fetal sheep were developed which gave high yields of cells. Myoblasts were grown in vitro, and allowed to fuse to form contractile multinucleate myotubes; these could be maintained in a good condition for at least 2 weeks. Protein turnover in these differentiated cultures was examined for sensitivity to each of four potentially anabolic peptide hormones and growth factors: insulin, insulin-like growth factor I (somatomedin C), epidermal growth factor and growth hormone. Insulin was found to have no effect except at high concentrations (1 μmol/l), compatible with its role as a somatomedin analogue. Insulin-like growth factor I was active at lower levels (1 nmol/l) but the cultures were not as responsive to it as were primary rat muscle cultures or differentiated L6 cells, which were tested in similar experiments. The maximum stimulation of protein synthesis observed with the ruminant system was only 16%. Epidermal growth factor was highly anabolic for primary cultures from sheep muscle, and the cells were very sensitive to it, half-maximal stimulation of protein synthesis being seen with concentrations as low as 20 pmol/l. No effects of bovine growth hormone were seen in the ovine system. However, an inhibition of protein breakdown was found with high concentrations (0·1 μmol/l) in the L6 rat myoblast cell line. It was found that the culture conditions used could affect the observed responses of protein synthesis and degradation, despite withdrawal of serum from the incubation media 22 h before testing. J. Endocr. (1987) 112, 87–96

Sign in / Sign up

Export Citation Format

Share Document